Infectious Diseases In Vitro Diagnostics Market

Publisher: AnalystView Market Insights
Publication Date: June, 2020
Healthcare / Medical Equipment
Pages: 190
Delivery Format: PDF

By Product (Reagents, Instruments, and Software), By Technology (Microbiology, Molecular Diagnostics, and Immunochemistry), By Application, By End Use (Central Laboratories, and Point of Care), and By Geography (NA, EU, APAC, LATAM and MEA) Ð Analysis, Share, Trends, Size, & Forecast From 2020 Ð 2026

Report Features
Table of Contents
Pricing
Methodology
Request Sample
Compare Offers
Make an Offer

REPORT HIGHLIGHT
Infectious Diseases In Vitro Diagnostics market was valued at USD 16.1 billion by 2019, growing with 7.3% CAGR during the forecast period, 2020-2026
Market Dynamics
The favorable government initiatives and the rise in external funds for R&D purposes are some of the major factors driving the growth of global infectious diseases in vitro diagnostics market. In addition, the increasing geriatric population all across the globe are other key factors boosting the market growth. According to the World Population Aging Report by United Nations (UN), in 2019, the number of elderly people aged 80 years and older were estimated for 143 million and this number is projected to reach 426 million by the end of 2050. Moreover, the shift towards self-care clinical devices, growing health awareness, and the rising burden of target diseases are some of the contributors to the growth of the global market for infectious diseases IVD market. Conversely, a dearth of stringent regulatory framework and expenses associated with in-vitro diagnostic tests are predicted to hinder the market growth during the forecast period. Furthermore, the advancements in IVD kits such as improved patient compliance, sensitivity, and speed is likely to create lucrative opportunities in the global market in the coming future.
Presently, the North America region is playing a leading role in the global infectious diseases IVD market and is estimated to dominate the industry throughout the forecast. This dominance is attributed to the presence of well-established healthcare infrastructure, proactive government initiatives, and growing awareness levels of patients and practitioners in this region.
Further key findings of the report suggest:
¥ The reagents product segment held the largest market share in the overall market in 2019 and is expected to grow at a healthy rate during the forecast period. This is mainly due to increasing demand for point-of-care & self-test products and the growth in the number of R&D initiatives related to molecular diagnostic tools.
¥ The HIV tests segment valued for the majority of share in the infectious diseases IVD market in 2019 owing to the rapidly rising disease burden and highly unmet medical needs in the developing countries.
¥ The immunochemistry technology segment accounted for the highest revenue share in the worldwide industry in 2019, followed thoroughly by molecular diagnostics. Nevertheless, molecular diagnostics technology is projected to be the largest segment by the end of 2030. This is mainly due to the increasing demand for rapid new-age, accurate, and sensitive devices and rising penetration for diagnosing infectious diseases.
¥ The central laboratories end use segment emerged as the largest in 2019, which is primarily driven by the large volume of tests carried out these laboratories. On the other hand, the point-of-care (PoC) end use segment is projected to witness the highest growth rate during the period of forecast. This is majorly owing to the rising need for rapid diagnosing and the increase in initiatives intended to lessen hospital stays to bound healthcare expenditure.
¥ The Asia Pacific market for infectious diseases IVD is projected to record the highest growth rate in the estimated period owing to the high unmet medical needs, presence of favorable government initiatives for testing infectious disease, the rise in healthcare spending in countries such as India, China, South Korea, and an increase in disposable income in this region.
¥ Key participants of the overall infectious diseases IVD market include bioMŽrieux SA, Alere Inc., Abbott, Quidel Corporation, Orasure Technologies, Inc., F. Hoffmann-La Roche Ltd., Cepheid, Qiagen N.V., Hologic Inc., and Siemens Healthcare GmbH.
The market size and forecast for each segment and sub-segments has been considered as below:
¥ Historical Year Ð 2015 to 2018
¥ Base Year Ð 2019
¥ Estimated Year Ð 2020
¥ Projected Year Ð 2026
TARGET AUDIENCE
? Traders, Distributors, and Suppliers
? Manufacturers
? Government and Regional Agencies
? Research Organizations
? Consultants
? Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL INFECTIOUS DISEASES IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY
? Molecular Diagnostics
? Immunochemistry
? Microbiology
? Others
GLOBAL INFECTIOUS DISEASES IN VITRO DIAGNOSTICS MARKET, BY PRODUCT
? Reagents
? Instruments
? Software
? Others
GLOBAL INFECTIOUS DISEASES IN VITRO DIAGNOSTICS MARKET, BY APPLICATION
? Gonorrhoea
? HPV
? HIV
? MRSA
? Streptococcus
? Clostridium Difficile
? VRE
? TB and Drug-resistant TB
? Gastro-intestinal Panel Testing
? Hepatitis B
? Hepatitis C
? CRE
? Respiratory Virus
? Candida
? Chlamydia
? Others
GLOBAL INFECTIOUS DISEASES IN VITRO DIAGNOSTICS MARKET, BY END USE
? Central Laboratories
? Point of Care
? Others
GLOBAL INFECTIOUS DISEASES IN VITRO DIAGNOSTICS MARKET, BY REGION
? North America
o The U.S.
o Canada
? Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Rest of Europe
? Asia Pacific
o India
o China
o South Korea
o Japan
o Singapore
o Rest of APAC
? Latin America
o Brazil
o Mexico
o Argentina
o Rest of LATAM
? Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Rest of MEA

Offer Amount (Per user license)	Retail price (Per user license)
$ .00	$3,250

Infectious Diseases In Vitro Diagnostics Market

Are you looking for a Consultant?

Customers Who Viewed This Item Also Viewed